<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Allergy Clin Immunol Glob</journal-id><journal-id journal-id-type="iso-abbrev">J Allergy Clin Immunol Glob</journal-id><journal-title-group><journal-title>The Journal of Allergy and Clinical Immunology: Global</journal-title></journal-title-group><issn pub-type="epub">2772-8293</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786640</article-id><article-id pub-id-type="pii">S2772-8293(24)00178-4</article-id><article-id pub-id-type="doi">10.1016/j.jacig.2024.100382</article-id><article-id pub-id-type="publisher-id">100382</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>ADP101 multifood oral immunotherapy for food-allergic patients: Harmony phase 1/2 randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Kim</surname><given-names>Edwin H.</given-names></name><degrees>MD, MS</degrees><email>edwinkim@email.unc.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Carr</surname><given-names>Warner W.</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Assa&#x02019;ad</surname><given-names>Amal H.</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Gogate</surname><given-names>Shaila U.</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Petroni</surname><given-names>Daniel H.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Casale</surname><given-names>Thomas B.</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Wang</surname><given-names>Mei-Lun</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Sullivan</surname><given-names>Amy</given-names></name><degrees>BA</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Archer</surname><given-names>Amy M.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Wang</surname><given-names>Ouhong</given-names></name><degrees>PhD</degrees><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Piscia-Nichols</surname><given-names>Cheri</given-names></name><degrees>BS</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Tuomi</surname><given-names>Lisa</given-names></name><degrees>PharmD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Levin-Young</surname><given-names>Olga</given-names></name><degrees>MBA</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Dombkowski</surname><given-names>Ashley</given-names></name><degrees>PhD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au15"><name><surname>McClintock</surname><given-names>Dana</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><on-behalf-of>on behalf of the </on-behalf-of><contrib contrib-type="author"><collab>Harmony investigators<xref rid="fn1" ref-type="fn">&#x02217;</xref></collab></contrib><aff id="aff1"><label>a</label>Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC</aff><aff id="aff2"><label>b</label>Allergy &#x00026; Asthma Providers of Southern California, Mission Viejo, Calif</aff><aff id="aff3"><label>c</label>Cincinnati Children&#x02019;s Hospital Medical Center, Cincinnati, Ohio</aff><aff id="aff4"><label>d</label>Colorado Allergy &#x00026; Asthma Centers PC, Denver, Colo</aff><aff id="aff5"><label>e</label>Seattle Allergy and Asthma Research Institute, Seattle, Wash</aff><aff id="aff6"><label>f</label>University of South Florida, Tampa, Fla</aff><aff id="aff7"><label>g</label>Alladapt Immunotherapeutics Inc, Menlo Park, Calif</aff><aff id="aff8"><label>h</label>PointOH5 LLC, Boston, Mass</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author: Edwin H. Kim, MD, MS, 5004 Mary Ellen Jones Bldg, 116 Manning Dr CB8035, Chapel Hill, NC 27599. <email>edwinkim@email.unc.edu</email></corresp><fn id="fn1"><label>&#x02217;</label><p id="ntpara0010">A complete list of Harmony investigators is provided in the Online Repository available at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0010">www.jaci-global.org</ext-link>.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>10</day><month>12</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>10</day><month>12</month><year>2024</year></pub-date><volume>4</volume><issue>1</issue><elocation-id>100382</elocation-id><history><date date-type="received"><day>17</day><month>5</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>7</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Oral immunotherapy is an established approach to desensitize the immune system in the context of allergic disease; however, the only currently approved product is for peanut allergy. ADP101 is a novel, pharmaceutical-grade, multifood oral immunotherapy in development to simultaneously treat single or multiple food allergies, containing allergenic proteins from 15 foods in equal parts by protein weight.</p></sec><sec><title>Objective</title><p>The phase 1/2 Harmony trial (NCT04856865) evaluated efficacy and safety of ADP101 in participants with qualifying allergy to 1 to 5 foods in ADP101, defined as dose-limiting symptoms with a &#x02264;100 mg challenge dose during double-blind, placebo-controlled food challenge (DBPCFC).</p></sec><sec><title>Methods</title><p>Participants were randomized to low-dose (1500 mg/d; 100 mg protein per food) or high-dose (4500 mg/d; 300 mg protein per food) ADP101, or matched placebo, with dose escalation followed by daily maintenance dosing over 40 weeks. The primary endpoint was the proportion of participants tolerating a &#x02265;600 mg challenge dose of a single qualifying food without dose-limiting symptoms at the Week 40 Exit DBPCFC (ie, responders).</p></sec><sec><title>Results</title><p>In the primary analysis population (61 pediatric participants aged 4-17 years), a greater response rate was observed in both the high-dose ADP101 (55.0%) and low-dose ADP101 (38.1%) groups compared with pooled placebo (20.0%) (nominal <italic>P</italic>&#x000a0;= .048, <italic>P</italic>&#x000a0;= .306, respectively; adjusted for multiple comparisons, <italic>P</italic>&#x000a0;= .097, <italic>P</italic>&#x000a0;= .306, respectively). Desensitization to &#x02265;2 foods was observed in individuals with multiple food allergies, as was desensitization at levels over 600 mg. ADP101-treated participants showed an overall reduction in skin-prick test reactivity, with an increase in maximum tolerated dose across the majority of foods tested. Adverse events were mostly mild or moderate, with no life-threatening events or deaths.</p></sec><sec><title>Conclusions</title><p>The study did not meet its primary endpoint, but ADP101 demonstrated a favorable safety profile and increased the reactive threshold in DBPCFC in pediatric participants with single or multiple food allergies across multiple endpoints, warranting further clinical investigation.</p></sec></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>Food allergy</kwd><kwd>multifood allergy</kwd><kwd>pediatric food allergy</kwd><kwd>allergy desensitization</kwd><kwd>oral immunotherapy</kwd><kwd>clinical trial</kwd></kwd-group></article-meta><def-list><title>Abbreviations used</title><def-item><term id="kwrd0045">AE</term><def><p>Adverse event</p></def></def-item><def-item><term id="kwrd0055">AESI</term><def><p>AE of special interest</p></def></def-item><def-item><term id="kwrd0065">COVID-19</term><def><p>Coronavirus disease 2019</p></def></def-item><def-item><term id="kwrd0075">DBPCFC</term><def><p>Double-blind, placebo-controlled food challenge</p></def></def-item><def-item><term id="kwrd0085">ED</term><def><p>Eliciting dose</p></def></def-item><def-item><term id="kwrd0095">EoE</term><def><p>Eosinophilic esophagitis</p></def></def-item><def-item><term id="kwrd0105">HD</term><def><p>High dose</p></def></def-item><def-item><term id="kwrd0115">ITT</term><def><p>Intent to treat</p></def></def-item><def-item><term id="kwrd0125">LD</term><def><p>Low dose</p></def></def-item><def-item><term id="kwrd0135">MTD</term><def><p>Maximum tolerated dose</p></def></def-item><def-item><term id="kwrd0145">OIT</term><def><p>Oral immunotherapy</p></def></def-item><def-item><term id="kwrd0155">QFA</term><def><p>Qualifying food allergy</p></def></def-item><def-item><term id="kwrd0165">SD</term><def><p>Standard deviation</p></def></def-item><def-item><term id="kwrd0175">SPT</term><def><p>Skin-prick test</p></def></def-item><def-item><term id="kwrd0185">TEAE</term><def><p>Treatment-emergent AE</p></def></def-item></def-list></front><body><p id="p0010">The incidence of food allergies is rising globally, estimated to affect up to 10% of the population.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref> Reactions can be serious or life-threatening, particularly in cases of anaphylaxis. In the United States, multifood allergy is common, with approximately 30% to 60% of food-allergic patients reacting to &#x0003e;1 food.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Multifood allergy increases the likelihood of accidental exposure, increases the challenges of allergen avoidance, and may present increased risk of nutritional deficiency.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> For patients and their families, food allergies can cause anxiety and social isolation, increase financial burden, and significantly affect quality of life.<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref></p><p id="p0015">Food allergy management options include dietary avoidance, education on acute treatment of allergic reactions, oral immunotherapy (OIT) for specific foods, and the anti-IgE monoclonal antibody omalizumab.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> OIT is a method of desensitization that can modulate allergic immune responses, with potential disease modifying effects;<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref> it was first described for single-food allergies in 1908,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> with efficacy now demonstrated in larger studies.<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref> Only one regulatory-approved OIT is currently available, a single-allergen treatment specifically for pediatric peanut allergy.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> This leaves a vast unmet need for single-allergen treatment of other prevalent food allergies, and for simultaneous treatment of multifood allergy. While studies show potential for parallel desensitization to multiple allergens using nonregulated commercial food sources as multifood OIT,<xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref> these treatments present challenges with regard to custom formulation, dose, and quality control.</p><p id="p0020">ADP101 is a novel, first-in-class multifood OIT drug product, a standardized pharmaceutical-grade dry powder containing proteins from 15 common allergenic foods:<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> almond, cashew, chicken&#x02019;s egg, codfish, cow&#x02019;s milk, hazelnut, peanut, pecan, pistachio, salmon, sesame, shrimp, soy, walnut, and wheat, in equal parts by protein weight. The Harmony trial evaluated the initial safety and efficacy of ADP101 in participants with single or multiple food allergies.</p><sec id="sec1"><title>Methods</title><p id="p0025">Harmony (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0015">ClinicalTrials.gov</ext-link>, NCT04856865) was a multicenter, phase 1/2 randomized, double-blind, placebo-controlled trial conducted in the United States from April 2021 to December 2022, in accordance with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation Good Clinical Practice guidelines, and applicable laws and regulations. Participants, or their legally authorized representatives, provided written informed consent before participation. All sites were approved by their institutional review board or independent ethics committee before initiation. An independent data monitoring committee provided oversight. Alladapt Immunotherapeutics Inc sponsored the trial and was involved in its design, conduct, data collection, and analysis. CONSORT (Consolidated Standards of Reporting Trials) reporting guidelines were adhered to.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> The trial protocol and statistical analysis plan are available in this article&#x02019;s Online Repository available at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0020">www.jaci-global.org</ext-link>.</p><sec id="sec1.1"><title>Trial population</title><p id="p0030">Eligible participants were 4 to 55 years of age; however, the prespecified primary analysis population was pediatric participants (age 4-17 years). Participants had 1 to 5 qualifying food allergies (QFAs), defined as dose-limiting symptoms with a &#x02264;100 mg challenge dose of almond, cashew, chicken&#x02019;s egg, codfish, cow&#x02019;s milk, hazelnut, peanut, pecan, pistachio, salmon, sesame, shrimp, soy, walnut, or wheat during double-blind, placebo-controlled food challenge (DBPCFC) at Screening. <xref rid="appsec1" ref-type="sec">Table E1</xref>, in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0025">www.jaci-global.org</ext-link>, lists complete enrollment criteria.</p></sec><sec id="sec1.2"><title>Trial design</title><p id="p0035">Eligible participants were randomized, then stratified by age (4-17 and 18-55 years, inclusive) 2:2:1:1 to ADP101 low dose (LD-ADP101; target dose 1500 mg/d [100 mg protein per food]), ADP101 high dose (HD-ADP101; target dose 4500 mg/d [300 mg protein per food]), placebo low dose, or placebo high dose. The randomization schedule was generated by an independent unblinded statistician by SAS software. Participants, assessing physicians, and participating site staff were unaware of the treatment group.</p><p id="p0040">Active study drug (ADP101) was a dry powder mixture of allergenic proteins from 15 food sources (almond, cashew, chicken&#x02019;s egg, codfish, cow&#x02019;s milk, hazelnut, peanut, pecan, pistachio, salmon, sesame, shrimp, soy, walnut, and wheat) in equal parts by protein weight. It was formulated with excipients including an aroma/flavor masker and isomalt, then packaged into premeasured doses. ADP101 was manufactured under pharmaceutical good manufacturing practice guidelines, with appropriate control of materials and process (ie, pharmaceutical grade). The product met US Food and Drug Administration requirements for administration to participants in a clinical trial setting and was released under an investigational new drug application.</p><p id="p0045">Placebo powder, provided in the same packaging as the active drug, contained excipients including an aroma/flavor masker and coloring agents to achieve similar appearance and total weight as ADP101. The study drug was mixed with a palatable, nonallergenic, age-appropriate food, taken orally daily. The maximum total volume was approximately 2 rounded tablespoons.</p><p id="p0050">In lieu of an initial dose-escalation day, Day 1 of treatment consisted of a single 5 mg dose of study drug at the trial site that, if tolerated, was continued daily at home for 2 weeks. Updosing (<xref rid="fig1" ref-type="fig">Fig 1</xref>) was attempted every 2 weeks in the clinic up to the randomized target dose, which was maintained through the Week 40 DBPCFCs. Patients unable to tolerate a dose level of &#x02265;50 mg study drug were discontinued.<fig id="fig1"><label>Fig 1</label><caption><p>Harmony trial design and updosing schedule. Updosing was attempted every 2 weeks and permitted through Week 38. Dose (in mg) refers to protein content. <italic>mOIT,</italic> Multifood OIT; <italic>R,</italic> randomization.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0055">A key feature of the updosing protocol was flexibility. Participants could attempt updosing &#x02264;3 times per dose level, with downdosing permitted per investigators&#x02019; clinical judgment at any time. Updosing was permitted through Week 38, after which the dose was maintained. Any participant able to sustain a maintenance dose of &#x02265;50 mg was eligible to complete the Week 40 DBPCFCs. After the final Exit DBPCFC, all participants continued treatment for up to 4 weeks in a blinded extension period, followed by the end-of-treatment visit, to maintain blinding during subject-level data cleaning. Participants were then unblinded in a rolling order. Eligible participants who completed the study could elect to continue in the open-label extension trial (Encore; NCT05243719).</p></sec><sec id="sec1.3"><title>Assessments</title><p id="p0060">DBPCFCs were performed at Screening for foods with a known clinical history, significant cross-reactivity to other food allergens (eg, cashews if allergic to pistachios), or unknown reactivity if skin-prick test (SPT) mean wheal diameter was &#x0003e;3 mm above negative control.</p><p id="p0065">DBPCFCs were performed again at Exit/Week 40 to assess desensitization to reactive foods and to assess neosensitization to foods not recently consumed but that had a &#x02265;3 mm increase at Week 38 over Screening in SPT mean wheal diameter (relative to negative control).</p><p id="p0070">The Harmony DBPCFC procedure was based on the 2012 PRACTALL consensus guidelines<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> with modified updosing schedules (see <xref rid="appsec1" ref-type="sec">Table E2</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0030">www.jaci-global.org</ext-link>). Participants were gradually fed increasing amounts of a suspected allergenic food or matched placebo, mixed with a palatable food, every 15 to 30 minutes, with 1 hour maximum between doses. The challenge was terminated if any symptom met the stopping criteria as per the study food challenge manual (ie, dose-limiting symptoms) and appropriate treatment provided. Eliciting dose (ED) for individual foods was defined as the dose level that elicited symptoms leading to DBPCFC termination. The maximum tolerated dose (MTD) was defined as the highest dose level tolerated during the DBPCFC.</p><p id="p0075">DBPCFCs were performed under direct medical supervision using sponsor-provided food challenge material prepared by unblinded site staff, administered by blinded site staff/investigators. During screening, the highest single dose level per food tested in the DBPCFC was 1000 mg protein (cumulative 2044 mg). Reactive foods were those with an ED of &#x02264;1000 mg, further categorized into qualifying foods (ED &#x02264;100 mg) or nonqualifying foods (ED &#x0003e;100 mg but &#x02264;1000 mg). During Exit DBPCFCs, the highest single dose level per food tested was 4000 mg protein (cumulative 8044 mg).</p><p id="p0080">Safety assessments included adverse events (AEs), serious AEs, and AEs of special interest (AESIs). Study-defined AESIs included anaphylaxis, AEs leading to epinephrine use, and eosinophilic esophagitis (EoE). AEs were classified using the Medical Dictionary for Regulatory Activities (MedDRA) v24.1. Severity of allergic AEs, including anaphylaxis, was graded with the Consortium for Food Allergy Research (CoFAR) Grading Scale v1.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Nonallergic AEs were graded with the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</p></sec><sec id="sec1.4"><title>Outcomes</title><p id="p0085">The primary endpoint was the proportion of participants tolerating a &#x02265;600 mg challenge dose of a single qualifying food (1044 mg cumulative) without dose-limiting symptoms at Exit DBPCFC. Secondary endpoints were the proportion of participants tolerating &#x02265;1000 mg of a single qualifying food, and, for participants with &#x0003e;1 QFA, tolerating &#x02265;600 mg or &#x02265;1000 mg of &#x02265;2 qualifying foods at Exit DBPCFC. Prespecified exploratory endpoints included change from baseline in SPT and ED; MTD; maximum severity of allergy symptoms at Screening and Exit DBPCFC; incidence of neosensitization; and accidental exposure. To further evaluate ADP101 at higher levels of desensitization, additional <italic>ad hoc</italic> efficacy analyses were conducted to identify participants tolerating the &#x02265;2000 or 4000 mg challenge dose of a qualifying food at Exit DBPCFC.</p></sec><sec id="sec1.5"><title>Statistical analysis</title><p id="p0090">The primary analysis population was the pediatric intent-to-treat (ITT) population, defined as all randomized participants aged 4 to 17 years, inclusive. The planned primary analysis population was 60 participants (20 in each of the HD-ADP101, LD-ADP101, and placebo groups). Adequacy of the sample size was confirmed by performing simulations for power calculations by Fisher exact test for each of 2 doses (vs placebo) under alternative hypotheses. Assuming placebo response rates of 4% and active response rates of 40% and 58% in the low- and high-dose regimen treatment groups, respectively (based on Vickery et&#x000a0;al<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref>) and an alpha of 5%, power was calculated by the Simes global test<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> with the Holm procedure<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> to reject &#x02265;1 of the doses. With a 20% dropout rate, results showed approximately 90% power to detect a statistically significant ADP101 response in &#x02265;1 of the doses with the given sample size.</p><p id="p0095">Unless otherwise specified, information was summarized descriptively by treatment arm, including number of patients, mean, standard deviation (SD), median, range for continuous variables, and number and percentage of nonmissing values per category for categorical data. Low- and high-dose placebo groups were pooled for analysis. The primary and secondary endpoints were binary data, and respective difference in the proportion of responders (those tolerating a &#x02265;600 mg challenge dose of &#x02265;1 qualifying food at Exit DBPCFC; ADP101 vs pooled placebo) with Newcombe 95% confidence intervals were reported together with the unadjusted <italic>P</italic> values by Fisher exact test. Participants missing Exit DBPCFC data were considered nonresponders unless otherwise specified. In the ITT analysis, to adjust for multiple comparisons for the primary endpoint, the Simes test with the Holm procedure was applied, comparing the lowest unadjusted <italic>P</italic> value against an adjusted threshold of 0.025 to test for statistical significance. In the supplemental ITT analysis, response status was imputed by multiple imputation with logistic regression for participants discontinuing for administrative reasons (eg, site closure); all other discontinuations were considered nonresponse. The logistic regression model included treatment group, number of qualifying food allergies, median specific IgE-to-IgG<sub>4</sub> ratio for qualifying foods at baseline, and history of asthma as covariates. Both adjusted and unadjusted <italic>P</italic> values are reported for the primary endpoint; subsequent analyses report the unadjusted (nominal) <italic>P</italic> value only. Analysis was performed by SAS v9.4 or higher.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Participants</title><p id="p0100">A total of 73 participants were randomized, including 61 pediatric and 12 adult participants (<xref rid="fig2" ref-type="fig">Fig 2</xref>) from 15 sites. Results presented here are for the study-defined primary analysis population (pediatric ITT population); results for adult participants are provided in <xref rid="appsec1" ref-type="sec">Fig E1</xref> and <xref rid="appsec1" ref-type="sec">Table E3</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0035">www.jaci-global.org</ext-link>.<fig id="fig2"><label>Fig 2</label><caption><p>Participant screening, randomization, and follow-up. Of 105 participants, 32 (31%) did not meet inclusion criteria (17%), had exclusion criteria (4%), or had another reason (10%) to be removed from study; other reasons included withdrawal of consent, time constraints, planned travel, investigator recommendation, SPT reaction not within protocol limits, and SPT-negative control reaction &#x0003e;3 mm. Primary analysis population (N&#x000a0;= 61) was the pediatric ITT population. In this group, 47 (77%) of 61 completed treatment, with 40 (66%) planning to continue in the OLE. Treatment discontinuation occurred in 14 (23%) of pediatric participants as a result of patient withdrawal (12%), AEs (7%), and other reasons (5%); other reasons included site closure/declined site transfer. One participant who discontinued treatment continued study participation through the end-of-treatment visit. All other participants who discontinued treatment also discontinued the study. Thirteen (21%) of 61 discontinued study, with primary reason being administration (8%), other (8%), and AE (5%); other reasons included withdrawal of consent because of product taste and/or texture, concerns over number of food challenges and school time missed, noncompliance, and inability to attend study visits. &#x02217;Twelve adult participants were included as a feasibility cohort; cases are described individually in Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0105">www.jaci-global.org</ext-link>. <italic>OLE,</italic> Open-label extension.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0105">In the pediatric ITT population, the median (range) age at Screening was 10 (4-17) years (<xref rid="tbl1" ref-type="table">Table I</xref>). QFAs to 14 of 15 components of ADP101 were represented in the pediatric ITT; moreover, 49.2% of participants had &#x02265;2 QFAs, and 45.9% of participants had reactive nonqualifying food allergies in addition to &#x02265;1 QFA (see <xref rid="appsec1" ref-type="sec">Table E4</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0040">www.jaci-global.org</ext-link>). The majority of participants had a history of anaphylaxis. Peanut, followed by cashew, were the most common QFAs. Multifood allergy was higher in the placebo group than in the active treatment groups; 60.0% (12/20), 42.9% (9/21), and 45.0% (9/20) of participants had &#x02265;2 QFAs in the placebo, LD-ADP101, and HD-ADP101 groups, respectively.<table-wrap position="float" id="tbl1"><label>Table I</label><caption><p>Baseline characteristics of pediatric ITT population</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Pooled placebo (n&#x000a0;= 20)</th><th>LD-ADP101 (n&#x000a0;= 21)</th><th>HD-ADP101 (n&#x000a0;= 20)</th></tr></thead><tbody><tr><td>Age at Screening (years)</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Mean [SD]</td><td align="center">10.1 [3.5]</td><td align="center">10.3 [3.4]</td><td align="center">9.9 [2.8]</td></tr><tr><td>&#x000a0;Median (range)</td><td align="center">9.5 (4-16)</td><td align="center">10.0 (5-17)</td><td align="center">10.0 (5-14)</td></tr><tr><td>Sex, no. (%)</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Male</td><td align="center">13 (65.0)</td><td align="center">14 (66.7)</td><td align="center">14 (70)</td></tr><tr><td>&#x000a0;Female</td><td align="center">7 (35.0)</td><td align="center">7 (33.3)</td><td align="center">6 (30.0)</td></tr><tr><td>Race, no. (%)</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;White</td><td align="center">10 (50.0)</td><td align="center">15 (71.4)</td><td align="center">16 (80.0)</td></tr><tr><td>&#x000a0;Asian</td><td align="center">5 (25.0)</td><td align="center">5 (23.8)</td><td align="center">2 (10.0)</td></tr><tr><td>&#x000a0;Black or African American</td><td align="center">3 (15.0)</td><td align="center">0</td><td align="center">0</td></tr><tr><td>&#x000a0;Other</td><td align="center">2 (10.0)</td><td align="center">1 (4.8)</td><td align="center">2 (10.0)</td></tr><tr><td>Total IgE at Screening (IU/mL)</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Mean [SD]</td><td align="center">559.5 [978.4]</td><td align="center">650.6 [597.6]</td><td align="center">811.4 [1567.3]</td></tr><tr><td>&#x000a0;Median (range)</td><td align="center">270.4 (28.4-4486.4)</td><td align="center">372.3 (7.5-2111.8)</td><td align="center">350.6 (34.5-6824.3)</td></tr><tr><td><bold>Qualifying reactive foods</bold></td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Food allergies per participant based on Screening DBPCFC, no. (%)</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;1</td><td align="center">8 (40.0)</td><td align="center">12 (57.1)</td><td align="center">11 (55.0)</td></tr><tr><td>&#x000a0;2</td><td align="center">5 (25.0)</td><td align="center">4 (19.0)</td><td align="center">3 (15.0)</td></tr><tr><td>&#x000a0;3</td><td align="center">3 (15.0)</td><td align="center">4 (19.0)</td><td align="center">2 (10.0)</td></tr><tr><td>&#x000a0;4</td><td align="center">2 (10.0)</td><td align="center">0</td><td align="center">2 (10.0)</td></tr><tr><td>&#x000a0;5</td><td align="center">2 (10.0)</td><td align="center">1 (4.8)</td><td align="center">2 (10.0)</td></tr><tr><td>Individual food allergies based on Screening DBPCFC, no. (%)</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Peanut</td><td align="center">11 (55.0)</td><td align="center">9 (42.9)</td><td align="center">12 (60.0)</td></tr><tr><td>&#x000a0;Cashew</td><td align="center">10 (50.0)</td><td align="center">7 (33.3)</td><td align="center">5 (25.0)</td></tr><tr><td>&#x000a0;Pistachio</td><td align="center">8 (40.0)</td><td align="center">4 (19.0)</td><td align="center">4 (20.0)</td></tr><tr><td>&#x000a0;Walnut</td><td align="center">5 (25.0)</td><td align="center">3 (14.3)</td><td align="center">3 (15.0)</td></tr><tr><td>&#x000a0;Chicken&#x02019;s egg</td><td align="center">1 (5.0)</td><td align="center">5 (23.8)</td><td align="center">3 (15.0)</td></tr><tr><td>&#x000a0;Pecan</td><td align="center">3 (15.0)</td><td align="center">3 (14.3)</td><td align="center">2 (10.0)</td></tr><tr><td>&#x000a0;Cow&#x02019;s milk</td><td align="center">3 (15.0)</td><td align="center">3 (14.3)</td><td align="center">1 (5.0)</td></tr><tr><td>&#x000a0;Hazelnut</td><td align="center">3 (15.0)</td><td align="center">0</td><td align="center">3 (15.0)</td></tr><tr><td>&#x000a0;Sesame seed</td><td align="center">0</td><td align="center">2 (9.5)</td><td align="center">1 (5.0)</td></tr><tr><td>&#x000a0;Almond</td><td align="center">1 (5.0)</td><td align="center">0</td><td align="center">1 (5.0)</td></tr><tr><td>&#x000a0;Codfish</td><td align="center">0</td><td align="center">0</td><td align="center">2 (10.0)</td></tr><tr><td>&#x000a0;Shrimp</td><td align="center">0</td><td align="center">0</td><td align="center">2 (10.0)</td></tr><tr><td>&#x000a0;Wheat</td><td align="center">0</td><td align="center">0</td><td align="center">2 (10.0)</td></tr><tr><td>&#x000a0;Salmon</td><td align="center">0</td><td align="center">1 (4.8)</td><td align="center">0</td></tr><tr><td>&#x000a0;Soy</td><td align="center">0</td><td align="center">0</td><td align="center">0</td></tr><tr><td>Baseline SPT (mm), mean [SD]</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Almond</td><td align="center">12.5 [NA]</td><td align="center"/><td align="center">8.0 [NA]</td></tr><tr><td>&#x000a0;Cashew</td><td align="center">12.3 [4.8]</td><td align="center">19.7 [11.1]</td><td align="center">19.1 [10.1]</td></tr><tr><td>&#x000a0;Chicken&#x02019;s egg</td><td align="center">16.5 [NA]</td><td align="center">13.1 [12.0]</td><td align="center">8.2 [8.5]</td></tr><tr><td>&#x000a0;Codfish</td><td align="center"/><td align="center"/><td align="center">3.8 [5.3]</td></tr><tr><td>&#x000a0;Cow&#x02019;s milk</td><td align="center">25.7 [24.8]</td><td align="center">12.7 [9.1]</td><td align="center">16.0 [NA]</td></tr><tr><td>&#x000a0;Hazelnut</td><td align="center">8.3 [5.8]</td><td align="center"/><td align="center">13.8 [14.0]</td></tr><tr><td>&#x000a0;Peanut</td><td align="center">9.9 [4.3]</td><td align="center">13.4 [7.7]</td><td align="center">15.7 [7.7]</td></tr><tr><td>&#x000a0;Pecan</td><td align="center">4.5 [7.8]</td><td align="center">0.0 [0.0]</td><td align="center">0.0 [0.0]</td></tr><tr><td>&#x000a0;Pistachio</td><td align="center">13.0 [6.6]</td><td align="center">23.6 [4.9]</td><td align="center">20.4 [8.1]</td></tr><tr><td>&#x000a0;Salmon</td><td align="center"/><td align="center">7.0 [NA]</td><td align="center"/></tr><tr><td>&#x000a0;Sesame seed</td><td align="center"/><td align="center">12.5 [4.2]</td><td align="center">7.5 [NA]</td></tr><tr><td>&#x000a0;Shrimp</td><td align="center"/><td align="center"/><td align="center">13.3 [8.8]</td></tr><tr><td>&#x000a0;Soy</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Walnut</td><td align="center">14.1 [7.6]</td><td align="center">8.0 [2.5]</td><td align="center">13.0 [10.6]</td></tr><tr><td>&#x000a0;Wheat</td><td align="center"/><td align="center"/><td align="center">4.9 [0.2]</td></tr><tr><td>Baseline sIgE (kU<sub>A</sub>/L), mean [SD]</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Almond</td><td align="center">14.1 [NA]</td><td align="center"/><td align="center">15.7 [NA]</td></tr><tr><td>&#x000a0;Cashew</td><td align="center">5.6 [5.1]</td><td align="center">23.0 [32.5]</td><td align="center">6.3 [9.1]</td></tr><tr><td>&#x000a0;Chicken&#x02019;s egg</td><td align="center">37.0 [NA]</td><td align="center">23.4 [31.7]</td><td align="center">1.3 [1.2]</td></tr><tr><td>&#x000a0;Codfish</td><td align="center"/><td align="center"/><td align="center">0.1 [NA]</td></tr><tr><td>&#x000a0;Cow&#x02019;s milk</td><td align="center">25.5 [34.8]</td><td align="center">40.7 [51.7]</td><td align="center">100.0 [NA]</td></tr><tr><td>&#x000a0;Hazelnut</td><td align="center">3.9 [2.9]</td><td align="center"/><td align="center">14.4 [14.9]</td></tr><tr><td>&#x000a0;Peanut</td><td align="center">39.4 [48.1]</td><td align="center">53.0 [38.7]</td><td align="center">32.5 [35.2]</td></tr><tr><td>&#x000a0;Pecan</td><td align="center">3.5 [2.4]</td><td align="center">34.1 [14.5]</td><td align="center">6.6 [9.1]</td></tr><tr><td>&#x000a0;Pistachio</td><td align="center">9.0 [7.7]</td><td align="center">40.1 [41.1]</td><td align="center">35.7 [44.0]</td></tr><tr><td>&#x000a0;Salmon</td><td align="center"/><td align="center">0.1 [NA]</td><td align="center"/></tr><tr><td>&#x000a0;Sesame seed</td><td align="center"/><td align="center">30.7 [37.3]</td><td align="center">36.5 [NA]</td></tr><tr><td>&#x000a0;Shrimp</td><td align="center"/><td align="center"/><td align="center">0.7 [0.8]</td></tr><tr><td>&#x000a0;Soy</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Walnut</td><td align="center">9.5 [11.3]</td><td align="center">60.1 [49.1]</td><td align="center">12.4 [12.3]</td></tr><tr><td>&#x000a0;Wheat</td><td align="center"/><td align="center"/><td align="center">86.0 [19.8]</td></tr><tr><td>Medical history, no. (%)</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>&#x000a0;Anaphylaxis</td><td align="center">16 [80.0]</td><td align="center">17 [81.0]</td><td align="center">10 [50.0]</td></tr><tr><td>&#x000a0;Asthma</td><td align="center">8 [40.0]</td><td align="center">8 [38.1]</td><td align="center">8 [40.0]</td></tr><tr><td>&#x000a0;Eczema</td><td align="center">4 [20.0]</td><td align="center">5 [23.8]</td><td align="center">3 [15.0]</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Qualifying reactive food defined as food eliciting reaction at &#x02264;100 mg during Screening DBPCFC.</p></fn><fn id="tlspara0010"><p><italic>NA,</italic> Not applicable; <italic>sIgE,</italic> specific IgE.</p></fn></table-wrap-foot></table-wrap></p><p id="p0110">A total of 78.7% (48/61) of participants completed the trial, with 77.0% (47/61) completing treatment. A&#x000a0;total of 21.3% (13/61) discontinued the trial (<xref rid="fig2" ref-type="fig">Fig 2</xref>); 1.6% (1/61) discontinued the study drug because of an AE but completed the trial. One site closed because of coronavirus disease 2019 (COVID-19)-related administrative reasons; 3 of 4 participants at this site discontinued the trial, and 1 transferred to another site and completed the trial.</p></sec><sec id="sec2.2"><title>Treatment and exposures</title><p id="p0115">Overall treatment compliance in the pediatric ITT population was &#x0003e;90% (see <xref rid="appsec1" ref-type="sec">Table E5</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0045">www.jaci-global.org</ext-link>). The target treatment dose was achieved in 90.0%, 76.2%, and 70.0% of placebo, LD-ADP101, and HD-ADP101 participants, respectively, over a median of 20.6, 20.6, and 24.2 weeks of updosing. Median time at maintenance dose was 142.0, 145.0, and 112.0 days in the placebo, LD-ADP101, and HD-ADP101 group, respectively.</p><p id="p0120">Median (range) maintenance dose was 4500 (1500-4500) mg, 1500 (50-1500) mg, and 4500 (50-4500) mg in the placebo, LD-ADP101, and HD-ADP101 group, respectively. A&#x000a0;total of 90.0% of pooled placebo and 75.6% of pooled ADP101 participants reached at least 1500 mg as their highest tolerated dose, with 100.0% of high-dose placebo and 65.0% of HD-ADP101 participants reaching 4500 mg as their highest tolerated dose.</p></sec><sec id="sec2.3"><title>Primary endpoint</title><p id="p0125">The proportion of pediatric ITT participants tolerating a &#x02265;600 mg challenge dose of &#x02265;1 qualifying food at Exit DBPCFC (ie, responders) was 20.0% (4/20), 38.1% (8/21), and 55.0% (11/20) for placebo, LD-ADP101, and HD-ADP101 participants, respectively (unadjusted <italic>P</italic> values vs placebo: LD-ADP101, <italic>P</italic>&#x000a0;= .306; HD-ADP101, <italic>P</italic>&#x000a0;= .048) (<xref rid="fig3" ref-type="fig">Fig 3</xref>, <italic>A</italic>). The trial did not meet its primary endpoint after adjustments for multiple comparisons (adjusted <italic>P</italic> values vs placebo: LD-ADP101, <italic>P</italic>&#x000a0;= .306; HD-ADP101, <italic>P</italic>&#x000a0;= .097).<fig id="fig3"><label>Fig 3</label><caption><p>Response rates for primary and secondary efficacy endpoints (pediatric participants). <bold>(A)</bold> Primary efficacy endpoint; participants tolerating &#x02265;600 mg of &#x02265;1 qualifying food at Exit DBPCFC. ITT population was defined as all randomized participants. The primary endpoint was not met after adjustment for multiple comparisons. In supplemental ITT analysis, response status was imputed using multiple imputation for participants discontinuing for administrative reasons; all other discontinuations were considered nonresponse. Per-protocol population is defined as all participants from ITT population without major protocol deviations that affect statistical analysis, conducted as a sensitivity analysis of primary efficacy endpoint. <bold>(B)</bold> Secondary efficacy endpoints. <italic>P</italic> values are unadjusted unless otherwise stated, determined by Fisher exact test. Adjusted <italic>P</italic> values were determined by Simes global test with Holm procedure. Error bars depict 95% CI of proportion, estimated by Clopper-Pearson exact method. Dose (in mg) refers to protein content. <italic>Adj,</italic> Adjusted; <italic>CI,</italic> confidence interval.</p></caption><graphic xlink:href="gr3"/></fig></p><p id="p0130">To accommodate challenges of the COVID-19 pandemic, a prespecified supplemental ITT analysis was performed in which responses were imputed by treatment group for participants who discontinued for reasons unrelated to study drug (eg, COVID-19&#x02013;related site closure). Using this hybrid estimand strategy, 21.5% placebo, 40.5% LD-ADP101, and 58.0% HD-ADP101 participants were responders (nominal <italic>P</italic> values vs placebo: LD-ADP101, <italic>P</italic>&#x000a0;= .185; HD-ADP101, <italic>P</italic>&#x000a0;= .013).</p><p id="p0135">In the pediatric per-protocol population (including only participants who completed Exit DBPCFC), 23.5%, 53.3%, and 68.8% of placebo, LD-ADP101, and HD-ADP101 participants, respectively, were responders (nominal <italic>P</italic>&#x000a0;values vs placebo: LD-ADP101, <italic>P</italic>&#x000a0;= .144; HD-ADP101, <italic>P</italic>&#x000a0;=&#x000a0;.015).</p></sec><sec id="sec2.4"><title>Secondary endpoints</title><p id="p0140">A total of 15.0%, 23.8%, and 50% of placebo, LD-ADP101, and HD-ADP101 participants tolerated a &#x02265;1000 mg challenge dose of &#x02265;1 qualifying food at Exit DBPCFC (<xref rid="fig3" ref-type="fig">Fig 3</xref>, <italic>B</italic>). Among participants with multiple food allergies (&#x0003e;1 QFA) in the placebo (n&#x000a0;= 12), LD-ADP101 (n&#x000a0;= 9), and HD-ADP101 (n&#x000a0;= 9) groups, respectively, 0, 22.2%, and 55.6% tolerated a &#x02265;600 mg challenge dose, and 0, 11.1%, and 44.4% tolerated a &#x02265;1000 mg challenge dose of &#x02265;2 qualifying foods.</p></sec><sec id="sec2.5"><title>ADP101 dose threshold analysis</title><p id="p0145">Rates of desensitization at the 600 mg or 1000 mg threshold to &#x02265;1 food were shown to be very low for participants unable to tolerate a &#x02265;1500 mg (100 mg protein per food) maintenance dose (0 for pooled placebo; &#x02264;10% response for pooled ADP101) (<xref rid="fig4" ref-type="fig">Fig 4</xref>). However, among LD-ADP101 and HD-ADP101 (pooled ADP101) participants who could tolerate a &#x02265;1500 mg maintenance dose, response rates increased to 58.1% (600 mg threshold) and 48.4% (1000 mg threshold). Among HD-ADP101 patients who reached the 4500 mg target maintenance dose (300 mg protein per food), 76.9% and 69.2% had 600 mg and 1000 mg desensitization thresholds, respectively. Similar results were observed in participants with multiple food allergies for desensitization to &#x02265;2 qualifying foods (<xref rid="fig4" ref-type="fig">Fig 4</xref>, <italic>C</italic> and <italic>D</italic>). This ADP101 dose threshold analysis was modified from that specified in the statistical analysis plan, including both LD-ADP101 and HD-ADP101 patients in the 1500 mg analyses as both groups provided the opportunity to achieve this dose.<fig id="fig4"><label>Fig 4</label><caption><p>Response rate in participants reaching or not reaching 1500 mg or 4500 mg of study drug (pediatric ITT population). ADP101 dose threshold analysis. Patients randomized to both LD-ADP101 and HD-ADP101 could reach 1500 mg dose (pooled ADP101), whereas only those randomized to HD-ADP101 could reach&#x000a0;4500 mg dose. Reached dose refers to participants who were treated with specified dose and tolerated this for &#x02265;2 weeks. <bold>(A)</bold> Participants with a&#x000a0;&#x02265;600 mg desensitization response to &#x02265;1 qualifying food at&#x000a0;exit DBPCFC. <bold>(B)</bold> Participants with a&#x000a0;&#x02265;1000 mg desensitization response to &#x02265;1 qualifying food at exit DBPCFC. <bold>(C)</bold> Participants with a&#x000a0;&#x02265;600 mg desensitization response to &#x02265;2 qualifying foods at exit DBPCFC. <bold>(D)</bold> Participants with a&#x000a0;&#x02265;1000 mg desensitization response to &#x02265;2 qualifying foods at exit DBPCFC. <italic>NA,</italic> Not applicable.</p></caption><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec2.6"><title>Subgroup analysis</title><p id="p0150">Individual food results were consolidated into 9 categories,<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> grouping tree nuts and finfish (see <xref rid="appsec1" ref-type="sec">Table E6</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0050">www.jaci-global.org</ext-link>). Four categories included &#x02265;1 participant from each treatment group: peanut, tree nut, chicken&#x02019;s egg, and cow&#x02019;s milk. Rates of tolerance to a &#x02265;600 mg challenge dose in the placebo, LD-ADP101, and HD-ADP101 treatment groups, respectively, were for peanut 9.1%, 11.1%, and 41.7%; tree nut 21.4%, 44.4%, and 71.4%; chicken&#x02019;s egg 0, 20.0%, and 0; and cow&#x02019;s milk 0, 66.7%, and 100.0%.</p></sec><sec id="sec2.7"><title><italic>Ad hoc</italic> analyses and exploratory endpoints</title><p id="p0155">In <italic>ad hoc</italic> analyses evaluating efficacy of ADP101 at higher levels of desensitization (<xref rid="fig5" ref-type="fig">Fig 5</xref>), the proportion of participants in the placebo, LD-ADP101 and HD-ADP101 treatment groups, respectively, tolerating the &#x02265;2000 mg challenge dose of &#x02265;1 qualifying food were 10.0%, 14.3%, and 40.0%; and of &#x02265;2 qualifying foods were 0, 11.1%, and 33.3%. Rates of tolerance to a &#x02265;4000 mg challenge dose of &#x02265;1 qualifying food were 5.0%, 14.3%, and 35.0%; and of &#x02265;2 qualifying foods 0, 0, and 33.3%.<fig id="fig5"><label>Fig 5</label><caption><p>Participants tolerating higher levels (&#x02265;2000 mg) of &#x02265;1 qualifying food (pediatric ITT population). <italic>Ad hoc</italic> efficacy analysis (not included in statistical analysis plan). Desensitization response defined as tolerating &#x02265;2000 mg or 4000 mg challenge dose without dose-limiting symptoms at Exit DBPCFC. All <italic>P</italic> values are unadjusted, determined by Fisher exact test. Error bars depict 95% CI of proportion, estimated by Clopper-Pearson exact method. <italic>CI,</italic> Confidence interval.</p></caption><graphic xlink:href="gr5"/></fig></p><p id="p0160">Results for prespecified exploratory endpoints, including change from baseline in SPT, MTD, and ED by individual food; maximum severity of allergy symptoms at DBPCFC; neosensitization; and accidental exposure, are included in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0055">www.jaci-global.org</ext-link> in <xref rid="appsec1" ref-type="sec">Figs E2</xref> and <xref rid="appsec1" ref-type="sec">E3</xref>, and <xref rid="appsec1" ref-type="sec">Tables E7</xref>, <xref rid="appsec1" ref-type="sec">E8</xref>, and <xref rid="appsec1" ref-type="sec">E9</xref>. ADP101-treated participants showed an overall reduction in SPT reactivity (<xref rid="appsec1" ref-type="sec">Fig E2</xref>), with an increase in MTD across the majority of foods tested (<xref rid="appsec1" ref-type="sec">Fig E3</xref> and <xref rid="appsec1" ref-type="sec">Table E7</xref>).</p></sec><sec id="sec2.8"><title>Safety</title><p id="p0165">A small proportion of participants experienced AEs on day 1, including 2 placebo-, 2 LD-ADP101&#x02013;, and 2 HD-ADP101&#x02013;treated participants (see <xref rid="appsec1" ref-type="sec">Table E10</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0060">www.jaci-global.org</ext-link>). These were mild or moderate in severity and did not result in study discontinuation.</p><p id="p0170">Most participants had &#x02265;1 treatment-emergent AE (TEAE) over&#x000a0;the treatment period, including 95.0% placebo-, 95.2% LD-ADP101&#x02013;, and 95.0% HD-ADP101&#x02013;treated participants&#x000a0;(<xref rid="tbl2" ref-type="table">Table II</xref>, and see <xref rid="appsec1" ref-type="sec">Table E11</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0065">www.jaci-global.org</ext-link>). The rate of TEAEs per dose was 5.4%,&#x000a0;6.0%, and 5.9% in the placebo, LD-ADP101, and HD-ADP101 groups, respectively. The majority of TEAEs were mild or moderate, occurring more frequently during updosing (<xref rid="appsec1" ref-type="sec">Table E10</xref>).<table-wrap position="float" id="tbl2"><label>Table II</label><caption><p>Overall summary of TEAEs in pediatric participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Category</th><th>Pooled placebo (n&#x000a0;= 20)</th><th>LD-ADP101 (n&#x000a0;= 21)</th><th>HD-ADP101 (n&#x000a0;= 20)</th></tr></thead><tbody><tr><td>Total number of TEAEs</td><td>295</td><td>327</td><td>318</td></tr><tr><td>Participants with any TEAE</td><td align="char">19 (95.0)</td><td align="char">20 (95.2)</td><td align="char">19 (95.0)</td></tr><tr><td>Participants with TEAE related to study drug</td><td align="char">12 (60.0)</td><td align="char">16 (76.2)</td><td align="char">15 (75.0)</td></tr><tr><td>Participants with TEAE due to accidental exposure</td><td align="char">3 (15.0)</td><td align="char">1 (4.8)</td><td align="char">5 (25.0)</td></tr><tr><td>Participants with TEAE due to Exit DBPCFC</td><td align="char">16 (80.0)</td><td align="char">15 (71.4)</td><td align="char">13 (65.0)</td></tr><tr><td>Participants with TEAE due to other trial procedure</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Participants with TEAE resulting in drug discontinuation</td><td align="char">1 (5.0)</td><td align="char">1 (4.8)</td><td align="char">2 (10.0)</td></tr><tr><td>Participants with TEAE resulting in drug interruption</td><td align="char">9 (45.0)</td><td align="char">9 (42.9)</td><td align="char">10 (50.0)</td></tr><tr><td>Participants with TEAE resulting in dose modification</td><td align="char">6 (30.0)</td><td align="char">9 (42.9)</td><td align="char">9 (45.0)</td></tr><tr><td>Participants with TEAE resulting in trial discontinuation</td><td align="char">1 (5.0)</td><td align="char">1 (4.8)</td><td align="char">1 (5.0)</td></tr><tr><td>Participants with TEAE with fatal outcome</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Allergic/nonallergic TEAEs</td><td/><td/><td/></tr><tr><td>&#x000a0;Participants with allergic TEAE</td><td align="char">17 (85.0)</td><td align="char">20 (95.2)</td><td align="char">16 (80.0)</td></tr><tr><td>&#x000a0;Participants with CoFAR grade 3 or higher allergic TEAE</td><td align="char">3 (15.0)</td><td align="char">2 (9.5)</td><td align="char">2 (10.0)</td></tr><tr><td>&#x000a0;Participants with CoFAR grade 4 or higher allergic TEAE</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#x000a0;Participants with CTCAE grade 3 or higher nonallergic TEAE</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#x000a0;Participants with CTCAE grade 4 or higher nonallergic TEAE</td><td>0</td><td>0</td><td>0</td></tr><tr><td>TESAEs</td><td/><td/><td/></tr><tr><td>&#x000a0;Participants with TESAE</td><td>0</td><td>0</td><td align="char">1 (5.0)</td></tr><tr><td>&#x000a0;Participants with TESAE related to trial drug</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#x000a0;Participants with TESAE due to accidental exposure</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#x000a0;Participants with TESAE due to Exit DBPCFC</td><td>0</td><td>0</td><td>0</td></tr><tr><td>&#x000a0;Participants with TESAE due to other trial procedure</td><td>0</td><td>0</td><td>0</td></tr><tr><td>AESIs</td><td/><td/><td/></tr><tr><td>&#x000a0;Participants with AESI</td><td align="char">11 (55.0)</td><td align="char">9 (42.9)</td><td align="char">10 (50.0)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as nos. (%). Allergic TEAEs were graded based on CoFAR Grading Scale v1; nonallergic TEAEs were graded based on National Cancer Institute CTCAE v5.0. <italic>CoFAR,</italic> Consortium of Food Allergy Research; <italic>CTCAE,</italic> Common Terminology Criteria for Adverse Events; <italic>TESAE,</italic> serious TEAE.</p></fn></table-wrap-foot></table-wrap></p><p id="p0175">Four of 61 participants discontinued the study drug as a result of AEs, 3 of whom entirely discontinued the trial (1 each in the placebo [anaphylaxis], LD-ADP101 [EoE], and HD-ADP101 [anxiety] groups). One participant in the HD-ADP101 group discontinued treatment because of dyspepsia but completed the trial.</p><p id="p0180">The majority of participants in the safety population experienced &#x02265;1 study drug-related TEAE&#x02014;60.0%, 76.2%, and 75.0% of the placebo, LD-ADP101, and HD-ADP101 groups, respectively (<xref rid="tbl2" ref-type="table">Table II</xref>). During dose maintenance, no TEAEs related to study drug occurred in &#x0003e;10% of any group, and there were no study drug-related TEAEs of anaphylaxis (see <xref rid="appsec1" ref-type="sec">Table E12</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0070">www.jaci-global.org</ext-link>).</p><p id="p0185">Overall rates of treatment-emergent AESI (including Exit DBPCFC) were balanced between groups, occurring in 55.0%, 42.9%, and 50.0% of placebo-, LD-ADP101&#x02013;, and HD-ADP101&#x02013;treated participants, respectively (<xref rid="tbl2" ref-type="table">Table II</xref>). One biopsy-confirmed case of EoE occurred in the LD-ADP101 group during updosing; this resolved (symptomatically and histologically) after treatment discontinuation. TEAEs leading to epinephrine use, and of anaphylaxis, were more frequent during updosing; these were primarily mild or moderate (<xref rid="tbl3" ref-type="table">Table III</xref>). Overall, grade 3 anaphylaxis was infrequent, and no grade 3 events were attributed to ADP101. No grade 4 anaphylaxis was reported.<table-wrap position="float" id="tbl3"><label>Table III</label><caption><p>AESIs in pediatric safety population</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Category</th><th colspan="3">Updosing phase<hr/></th><th colspan="3">Dose-maintenance phase<hr/></th></tr><tr><th>Pooled placebo (n&#x000a0;= 20)</th><th>LD-ADP101 (n&#x000a0;= 21)</th><th>HD-ADP101 (n&#x000a0;= 20)</th><th>Pooled placebo (n&#x000a0;= 20)</th><th>LD-ADP101 (n&#x000a0;= 21)</th><th>HD-ADP101 (n&#x000a0;= 20)</th></tr></thead><tbody><tr><td>Participants with &#x02265;1 AESI</td><td align="char">3 (15.0)</td><td align="char">5 (23.8)</td><td align="char">7 (35.0)</td><td align="char">1 (5.0)</td><td align="char">0</td><td align="char">1 (5.0)</td></tr><tr><td>&#x000a0;Participants with &#x02265;1 anaphylaxis event</td><td align="char">3 (15.0)</td><td align="char">4 (19.0)</td><td align="char">6 (30.0)</td><td align="char">1 (5.0)</td><td align="char">0</td><td align="char">1 (5.0)</td></tr><tr><td>&#x000a0;Grade 3 or higher (severe)</td><td align="char">1 (5.0)</td><td>0</td><td align="char">1 (5.0)</td><td>0</td><td align="char">0</td><td>0</td></tr><tr><td>&#x000a0;Grade 4 or higher (life-threatening)</td><td>0</td><td>0</td><td>0</td><td>0</td><td align="char">0</td><td>0</td></tr><tr><td>Participants with &#x02265;1 epinephrine use</td><td align="char">1 (5.0)</td><td align="char">3 (14.3)</td><td align="char">7 (35.0)</td><td align="char">1 (5.0)</td><td align="char">0</td><td align="char">1 (5.0)</td></tr><tr><td>&#x000a0;AE prompting epinephrine use</td><td align="char">1 (5.0)</td><td align="char">3 (14.3)</td><td align="char">7 (35.0)</td><td align="char">1 (5.0)</td><td align="char">0</td><td align="char">1 (5.0)</td></tr><tr><td>&#x000a0;Related to study drug</td><td align="char">1 (5.0)</td><td align="char">2 (9.5)</td><td align="char">5 (25.0)</td><td>0</td><td align="char">0</td><td>0</td></tr><tr><td>&#x000a0;Accidental exposure</td><td>0</td><td>0</td><td>0</td><td align="char">1 (5.0)</td><td align="char">0</td><td align="char">1 (5.0)</td></tr><tr><td>&#x000a0;Other</td><td>0</td><td align="char">1 (4.8)</td><td align="char">2 (10.0)</td><td>0</td><td align="char">0</td><td>0</td></tr><tr><td>Severity of TEAE prompting epinephrine use</td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Grade 1 (mild)</td><td>0</td><td>0</td><td align="char">4 (20.0)</td><td>0</td><td align="char">0</td><td>0</td></tr><tr><td>&#x000a0;Grade 2 (moderate)</td><td>0</td><td align="char">3 (14.3)</td><td align="char">2 (10.0)</td><td align="char">1 (5.0)</td><td align="char">0</td><td align="char">1 (5.0)</td></tr><tr><td>&#x000a0;Grade 3 (severe)</td><td align="char">1 (5.0)</td><td>0</td><td align="char">1 (5.0)<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref></td><td>0</td><td align="char">0</td><td>0</td></tr><tr><td>&#x000a0;Grade 4 (life-threatening)</td><td>0</td><td>0</td><td>0</td><td>0</td><td align="char">0</td><td>0</td></tr><tr><td>&#x000a0;Grade 5 (death)</td><td>0</td><td>0</td><td>0</td><td>0</td><td align="char">0</td><td>0</td></tr><tr><td>Participants with &#x02265;1 EoE event</td><td>0</td><td align="char">1 (4.8)<xref rid="tbl3fndagger" ref-type="table-fn">&#x02020;</xref></td><td>0</td><td>0</td><td align="char">0</td><td>0</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as nos. (%). Anaphylaxis grading based on Consortium of Food Allergy Research (CoFAR) Grading Scale v1. Participants who experienced multiple events within AESI type were counted once for that AESI type.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnlowast"><label>&#x02217;</label><p id="ntpara0015">Cause unknown; occurred during early weeks of updosing before desensitization might be expected and in setting of potential accidental exposure to allergen. This event was considered serious because it required hospitalization for observation.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fndagger"><label>&#x02020;</label><p id="ntpara0020">Biopsy-confirmed EoE occurring approximately 4 weeks after reaching target dose of 1500 mg; participant discontinued treatment, and disease showed histologic resolution at repeat endoscopy.</p></fn></table-wrap-foot></table-wrap></p><p id="p0190">There was 1 serious AE (anaphylaxis; <xref rid="tbl3" ref-type="table">Table III</xref>) reported, and no life-threatening TEAEs or deaths (<xref rid="tbl2" ref-type="table">Table II</xref>).</p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0195">ADP101 is a novel investigational multifood OIT that includes 15 foods, which are representative of the food groups implicated in &#x0003e;90% of food allergies.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> While the primary endpoint was not met in the Harmony trial, ADP101 increased the reactive threshold in pediatric participants with single and multiple food allergies, with increased response rate at a higher dose of ADP101 observed across sensitivity analyses of the primary endpoint and by multiple prespecified subgroup and exploratory analyses. Evidence of desensitization was observed across most individual foods in ADP101-treated participants.</p><p id="p0200">The 600 mg desensitization threshold for the primary efficacy endpoint is clinically meaningful and represents a &#x02265;6-fold increase in the MTD. For peanut-allergic patients, increasing the threshold from &#x02264;100 mg protein to 300 mg reduces the risk of allergic reaction by &#x0003e;95% in the event of trace contamination.<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> An increase to 600 mg, used as the primary endpoint for PALISADE (peanut OIT)<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> and Harmony, has the potential to confer additional risk reduction. In this trial, desensitization to &#x02265;600 mg of peanut protein was observed in 41.7% of allergic HD-ADP101&#x02013;treated participants who completed Exit DBPCFC (9.1% and 11.1% in placebo- and LD-ADP101&#x02013;treated participants, respectively). Cashew was the second most prevalent allergy, with 50.0% of HD-ADP101&#x02013;treated allergic participants who completed Exit DBPCFC experiencing tolerance to &#x02265;600 mg (11.1% and 60.0% in placebo- and LD-ADP101&#x02013;treated participants, respectively).</p><p id="p0205">In prespecified subgroup analyses, response rate was enhanced in ADP101-treated participants who could tolerate 1500 mg/d (100 mg protein per food), and further in those who could tolerate 4500 mg/d (300 mg protein per food); 77% (10/13) of participants tolerating 4500 mg/d had disease that responded to therapy. This highlights 300 mg protein per food as the most likely effective dose for desensitization. Combined with similar rates of treatment-related AEs in LD-ADP101 and HD-ADP101 treatment groups, this supports further study of ADP101 with 4500&#x000a0;mg/d as the target dose, potentially with a longer treatment duration.</p><p id="p0210">Evidence for desensitization at higher challenge dose levels (2000 mg, 4000 mg) was observed in <italic>ad hoc</italic> analyses, with desensitization to 4000 mg of &#x02265;2 qualifying foods observed in &#x0003e;30% of HD-ADP101 participants with multiple food allergies. Within the limitations of small study size, this observation is encouraging; this level of oral tolerance far exceeds currently approved standards for desensitization in OIT clinical trials.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> For example, a 4000 mg challenge dose of peanut is equivalent to approximately 16 peanuts (see <xref rid="appsec1" ref-type="sec">Table E13</xref> in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0075">www.jaci-global.org</ext-link>)&#x02014;a potentially life-changing improvement from a baseline MTD of 3 mg (&#x0223c;1/80 of a single peanut).<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></p><p id="p0215">Although TEAEs were comparable across all 3 treatment groups, and those related to study drug were comparable between LD-ADP101 and HD-ADP101, suggestive of no dose-dependent safety signals, there were more AESIs attributable to HD-ADP101 in the updosing phase. Overall, ADP101 demonstrated a safety profile expected for an OIT product.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> The majority of AEs were mild or moderate in severity; they were most frequently reported during updosing, with decreased frequency during dose maintenance. In contrast to other OIT trials that require an initial dose-escalation day,<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> all Harmony participants received the same single starting dose of 5 mg (0.33 mg protein per food in ADP101) on Day 1, which was continued daily for 2 weeks. AE rates are typically high during a dose-escalation day; however, in Harmony, Day 1 AEs were infrequent. The patient- and provider-centric low-and-slow approach was devised to improve tolerability and reduce clinical burden, with no apparent loss of efficacy. Notably, there was no difference in the rate of neosensitization between placebo- and ADP101-treated participants, with one instance each in the placebo and LD-ADP101 groups (both hazelnut; see the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0080">www.jaci-global.org</ext-link>), suggesting that dosing with multiple allergenic foods does not pose a risk of sensitization in those who are not allergic to them.</p><p id="p0220">Small sample size was a limitation of this study, contributing to variation in some baseline characteristics across the 3 groups. In addition, variable prevalence of individual allergies within each group precluded comparisons between ADP101 and placebo for several foods. The estimated sample size (N&#x000a0;= 60) was based on placebo response rate for the approved single food (peanut) OIT, which was very low (5/124, 4%).<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Our study&#x02019;s placebo response rate was higher than anticipated (4/21, 21%), the result of 4 participants tolerating a &#x02265;600 mg challenge dose of 1 qualifying food at Exit DBPCFC (peanut, pistachio, cashew, or hazelnut). Spontaneous response was observed to be more likely in those with single allergies&#x02014;notably, no participant in the placebo group with multifood allergy could tolerate &#x02265;600 mg or &#x02265;1000 mg of &#x02265;2 qualifying foods at Exit DBPCFC.</p><p id="p0225">Beyond approved peanut monotherapy,<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> patients with food allergy have limited options for OIT, including nonregulated&#x000a0;commercial food sources, with their protein content varying&#x000a0;in unknown ways. ADP101, with a precise mixture of pharmaceutical-grade allergenic proteins from 15 food sources, has the potential to offer a standardized OIT option for those with a range of prevalent single food allergies, or with multifood allergy, which affects up to 60% of food-allergic patients in the United States.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> In contrast to existing options, a precisely characterized, pharmaceutical-grade comprehensive OIT such as ADP101 would ensure consistent quality, enable straightforward prescribing and pharmacy stocking, and potentially ease the burden on clinicians and multiallergic families. The approval of the monoclonal antibody omalizumab for those with multifood allergy<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> represents important progress in the field; however, accompanying limitations, including the need for regular injections and unclear accessibility as a result of cost, mean that further options are required to address the diverse needs of the food allergy population. Further, anti-IgE therapy and OIT have the potential to be combined in a synergistic approach.</p><p id="p0230">In conclusion, ADP101 increased the reactive threshold in pediatric participants with single or multiple food allergies, with a favorable safety profile. The trial did not meet its primary endpoint, but the data offer important insights that warrant further clinical investigation of ADP101.<boxed-text id="dtbox1"><caption><title>Clinical implication</title></caption><p id="p0235">ADP101, an OIT candidate covering the 15 most prevalent food allergens, was well tolerated and increased the reactive threshold in pediatric participants with single or multiple food allergies, warranting its further investigation.</p></boxed-text></p></sec><sec sec-type="COI-statement" id="coi0010"><title>Disclosure statement</title><p id="p0240">The Harmony trial was funded by <funding-source id="gs17">Alladapt Immunotherapeutics Inc</funding-source>.</p><p id="p0245">Disclosure of potential conflict of interest: E. Kim is a consultant for ALK-Abello, Belhaven BioPharma, Cellergy Pharma, DBV Technologies, Genentech, Hanimune Therapeutics, Kenota Health, Novartis, <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001720</institution-id><institution>Nutricia Research Foundation</institution></institution-wrap></funding-source>, Phylaxis, Revolo Biotherapeutics, and Ukko; and receives grant funding to his institution from the National Institute of Allergy and Infectious Diseases and <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006423</institution-id><institution>Food Allergy Research and Education</institution></institution-wrap></funding-source> (FARE). W. Carr is an employee of Allergy &#x00026; Asthma Associates of Southern California; a researcher for Southern California Research; a consultant for Alladapt Immunotherapeutics Inc, Aluna, Hikma Pharmaceuticals, and Merck; an advisor for Amgen, AstraZeneca, and Hikma Pharmaceuticals; a speaker for AstraZeneca, Regeneron Pharmaceuticals, and Sanofi; and has an executive role/ownership interest in Allergy &#x00026; Asthma Associates of Southern California. A. Assa&#x02019;ad has received grant funding to their institution from AbbVie, Aimmune Therapeutics, Alladapt Immunotherapeutics Inc, DBV Technologies, FARE, <funding-source id="gs14"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source>, Novartis, Sanofi, and Siolta; an internal research grant from Cincinnati Children&#x02019;s Hospital Medical Centre; and is a holder of patent US7732135 (Genetic Marker of Food Allergy). S. Gogate has participated in advisory boards for IgGenix and Novartis. D. Petroni is a consultant for Aimmune Therapeutics, Alladapt Immunotherapeutics Inc, ARS Pharmaceuticals, DBV Technologies, Roche-Genentech, and Takeda Pharmaceuticals. T. Casale is a consultant for AstraZeneca, Genentech, Jasper Therapeutics, Lily, Novartis, Regeneron Pharmaceuticals, and Sanofi; and a member of the speakers&#x02019; bureau for Genentech and Novartis. O. Wang provided biostatistics support to Alladapt Immunotherapeutics Inc for the Harmony trial. M. Wang, A. Sullivan, A. Archer, C. Piscia-Nichols, L. Tuomi, O. Levin-Young, A. Dombkowski, and D. McClintock are current or previous employees of Alladapt Immunotherapeutics Inc.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Sicherer</surname><given-names>S.H.</given-names></name><name><surname>Sampson</surname><given-names>H.A.</given-names></name></person-group><article-title>Food allergy: epidemiology, pathogenesis, diagnosis, and treatment</article-title><source>J Allergy Clin Immunol</source><volume>133</volume><year>2014</year><fpage>291</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.11.020</pub-id><pub-id pub-id-type="pmid">24388012</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R.S.</given-names></name><name><surname>Warren</surname><given-names>C.M.</given-names></name><name><surname>Smith</surname><given-names>B.M.</given-names></name><name><surname>Blumenstock</surname><given-names>J.A.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Davis</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>The public health impact of parent-reported childhood food allergies in the United&#x000a0;States</article-title><source>Pediatrics</source><volume>142</volume><year>2018</year><object-id pub-id-type="publisher-id">e20181235</object-id><pub-id pub-id-type="doi">10.1542/peds.2018-1235</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R.S.</given-names></name><name><surname>Warren</surname><given-names>C.M.</given-names></name><name><surname>Smith</surname><given-names>B.M.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Blumenstock</surname><given-names>J.A.</given-names></name><name><surname>Davis</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Prevalence and severity of food allergies among US adults</article-title><source>JAMA Netw Open</source><volume>2</volume><year>2019</year><object-id pub-id-type="publisher-id">e185630</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.5630</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>M.L.K.</given-names></name></person-group><article-title>The epidemiology of food allergy in the global context</article-title><source>Int J&#x000a0;Environ Res Public Health</source><volume>15</volume><year>2018</year><fpage>2043</fpage><pub-id pub-id-type="doi">10.3390/ijerph15092043</pub-id><pub-id pub-id-type="pmid">30231558</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Management of the patient with multiple food allergies</article-title><source>Curr Allergy Asthma Rep</source><volume>10</volume><year>2010</year><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1007/s11882-010-0116-0</pub-id><pub-id pub-id-type="pmid">20431971</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>R.</given-names></name><name><surname>De Koker</surname><given-names>C.</given-names></name><name><surname>Dziubak</surname><given-names>R.</given-names></name><name><surname>Venter</surname><given-names>C.</given-names></name><name><surname>Dominguez-Ortega</surname><given-names>G.</given-names></name><name><surname>Cutts</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Malnutrition in children with food allergies in the UK</article-title><source>J Hum Nutr Diet</source><volume>27</volume><year>2014</year><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1111/jhn.12149</pub-id><pub-id pub-id-type="pmid">23937486</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H.N.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Yum</surname><given-names>H.Y.</given-names></name></person-group><article-title>Nutritional status according to sensitized food allergens in children with atopic dermatitis</article-title><source>Allergy Asthma Immunol Res</source><volume>3</volume><year>2011</year><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.4168/aair.2011.3.1.53</pub-id><pub-id pub-id-type="pmid">21217926</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Flammarion</surname><given-names>S.</given-names></name><name><surname>Santos</surname><given-names>C.</given-names></name><name><surname>Guimber</surname><given-names>D.</given-names></name><name><surname>Jouannic</surname><given-names>L.</given-names></name><name><surname>Thumerelle</surname><given-names>C.</given-names></name><name><surname>Gottrand</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Diet and nutritional status of children with food allergies</article-title><source>Pediatr Allergy Immunol</source><volume>22</volume><year>2011</year><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3038.2010.01028.x</pub-id><pub-id pub-id-type="pmid">20561235</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>B.L.</given-names></name><name><surname>Noone</surname><given-names>S.</given-names></name><name><surname>Mu&#x000f1;oz-Furlong</surname><given-names>A.</given-names></name><name><surname>Sicherer</surname><given-names>S.H.</given-names></name></person-group><article-title>Development of a questionnaire to measure quality of life in families with a child with food allergy</article-title><source>J Allergy Clin Immunol</source><volume>114</volume><year>2004</year><fpage>1159</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2004.08.007</pub-id><pub-id pub-id-type="pmid">15536425</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>A.T.</given-names></name><name><surname>Ahlstedt</surname><given-names>S.</given-names></name><name><surname>Golding</surname><given-names>M.A.</given-names></name><name><surname>Protudjer</surname><given-names>J.L.P.</given-names></name></person-group><article-title>The economic burden of food allergy: what we know and what we need to learn</article-title><source>Curr Treat Options Allergy</source><volume>9</volume><year>2022</year><fpage>169</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1007/s40521-022-00306-5</pub-id><pub-id pub-id-type="pmid">35502316</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Lebovidge</surname><given-names>J.S.</given-names></name><name><surname>Stone</surname><given-names>K.D.</given-names></name><name><surname>Twarog</surname><given-names>F.J.</given-names></name><name><surname>Raiselis</surname><given-names>S.W.</given-names></name><name><surname>Kalish</surname><given-names>L.E.</given-names></name><name><surname>Bailey</surname><given-names>E.P.</given-names></name><etal/></person-group><article-title>Development of a preliminary questionnaire to assess parental response to children&#x02019;s food allergies</article-title><source>Ann Allergy Asthma Immunol</source><volume>96</volume><year>2006</year><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/s1081-1206(10)60916-7</pub-id><pub-id pub-id-type="pmid">16597083</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Wassenberg</surname><given-names>J.</given-names></name><name><surname>Cochard</surname><given-names>M.-M.</given-names></name><name><surname>DunnGalvin</surname><given-names>A.</given-names></name><name><surname>Ballabeni</surname><given-names>P.</given-names></name><name><surname>Flokstra-de Blok</surname><given-names>B.M.J.</given-names></name><name><surname>Newman</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Parent perceived quality of life is age-dependent in children with food allergy</article-title><source>Pediatr Allergy Immunol</source><volume>23</volume><year>2012</year><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3038.2012.01310.x</pub-id><pub-id pub-id-type="pmid">22554401</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="other" id="sref13"><person-group person-group-type="author"><collab>Xolair&#x000ae; (omalizumab)</collab></person-group><article-title>Prescribing information</article-title><comment>Genentech</comment><ext-link ext-link-type="uri" xlink:href="https://www.gene.com/download/pdf/xolair_prescribing.pdf" id="intref0090">https://www.gene.com/download/pdf/xolair_prescribing.pdf</ext-link><year>Revised February 2024</year></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>R.A.</given-names></name><name><surname>Togias</surname><given-names>A.</given-names></name><name><surname>Sicherer</surname><given-names>S.H.</given-names></name><name><surname>Shreffler</surname><given-names>W.G.</given-names></name><name><surname>Kim</surname><given-names>E.H.</given-names></name><name><surname>Jones</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Omalizumab for the treatment of multiple food allergies</article-title><source>N Engl J Med</source><volume>390</volume><year>2024</year><fpage>889</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2312382</pub-id><pub-id pub-id-type="pmid">38407394</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Kaushik</surname><given-names>A.</given-names></name><name><surname>Dunham</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Do</surname><given-names>E.</given-names></name><name><surname>Andorf</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><etal/></person-group><article-title>CD8<sup>+</sup> T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy</article-title><source>Nat Commun</source><volume>13</volume><year>2022</year><fpage>6646</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-34222-8</pub-id><pub-id pub-id-type="pmid">36333296</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Kulis</surname><given-names>M.D.</given-names></name><name><surname>Patil</surname><given-names>S.U.</given-names></name><name><surname>Wambre</surname><given-names>E.</given-names></name><name><surname>Vickery</surname><given-names>B.P.</given-names></name></person-group><article-title>Immune mechanisms of oral immunotherapy</article-title><source>J Allergy Clin Immunol</source><volume>141</volume><year>2018</year><fpage>491</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2017.12.979</pub-id><pub-id pub-id-type="pmid">29288078</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Tordesillas</surname><given-names>L.</given-names></name><name><surname>Berin</surname><given-names>M.C.</given-names></name></person-group><article-title>Mechanisms of oral tolerance</article-title><source>Clin Rev Allergy Immunol</source><volume>55</volume><year>2018</year><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1007/s12016-018-8680-5</pub-id><pub-id pub-id-type="pmid">29488131</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Schoos</surname><given-names>A.M.</given-names></name><name><surname>Bullens</surname><given-names>D.</given-names></name><name><surname>Chawes</surname><given-names>B.L.</given-names></name><name><surname>Costa</surname><given-names>J.</given-names></name><name><surname>De Vlieger</surname><given-names>L.</given-names></name><name><surname>DunnGalvin</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Immunological outcomes of allergen-specific immunotherapy in food allergy</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">568598</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.568598</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Schofield</surname><given-names>A.</given-names></name></person-group><article-title>A case of egg poisoning</article-title><source>Lancet</source><volume>171</volume><issue>4410</issue><year>1908</year><fpage>716</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)67313-0</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Varshney</surname><given-names>P.</given-names></name><name><surname>Jones</surname><given-names>S.M.</given-names></name><name><surname>Scurlock</surname><given-names>A.M.</given-names></name><name><surname>Perry</surname><given-names>T.T.</given-names></name><name><surname>Kemper</surname><given-names>A.</given-names></name><name><surname>Steele</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response</article-title><source>J Allergy Clin Immunol</source><volume>127</volume><year>2011</year><fpage>654</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2010.12.1111</pub-id><pub-id pub-id-type="pmid">21377034</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Nowak-W&#x00119;grzyn</surname><given-names>A.</given-names></name><name><surname>Wood</surname><given-names>R.A.</given-names></name><name><surname>Nadeau</surname><given-names>K.C.</given-names></name><name><surname>Pongracic</surname><given-names>J.A.</given-names></name><name><surname>Henning</surname><given-names>A.K.</given-names></name><name><surname>Lindblad</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy</article-title><source>J Allergy Clin Immunol</source><volume>143</volume><year>2019</year><fpage>651</fpage><lpage>661.e9</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2018.08.041</pub-id><pub-id pub-id-type="pmid">30389226</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>S.</given-names></name><name><surname>Kitamura</surname><given-names>K.</given-names></name><name><surname>Makino</surname><given-names>A.</given-names></name><name><surname>Matsui</surname><given-names>T.</given-names></name><name><surname>Furuta</surname><given-names>T.</given-names></name><name><surname>Takasato</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Slow low-dose oral immunotherapy: threshold and immunological change</article-title><source>Allergol Int</source><volume>69</volume><year>2020</year><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1016/j.alit.2020.03.008</pub-id><pub-id pub-id-type="pmid">32444309</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.H.</given-names></name><name><surname>Perry</surname><given-names>T.T.</given-names></name><name><surname>Wood</surname><given-names>R.A.</given-names></name><name><surname>Leung</surname><given-names>D.Y.M.</given-names></name><name><surname>Berin</surname><given-names>M.C.</given-names></name><name><surname>Burks</surname><given-names>A.W.</given-names></name><etal/></person-group><article-title>Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy</article-title><source>J Allergy Clin Immunol</source><volume>146</volume><year>2020</year><fpage>851</fpage><lpage>862.e10</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2020.05.040</pub-id><pub-id pub-id-type="pmid">32535135</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>M.</given-names></name><name><surname>Imai</surname><given-names>T.</given-names></name><name><surname>Ishikawa</surname><given-names>R.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name><name><surname>Kamiya</surname><given-names>T.</given-names></name><name><surname>Kimura</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Effect of oral immunotherapy in children with milk allergy: the ORIMA study</article-title><source>Allergol Int</source><volume>70</volume><year>2021</year><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.alit.2020.09.011</pub-id><pub-id pub-id-type="pmid">33248880</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Dantzer</surname><given-names>J.</given-names></name><name><surname>Dunlop</surname><given-names>J.</given-names></name><name><surname>Psoter</surname><given-names>K.J.</given-names></name><name><surname>Keet</surname><given-names>C.</given-names></name><name><surname>Wood</surname><given-names>R.</given-names></name></person-group><article-title>Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: a randomized, double-blind, placebo-controlled phase 2 trial</article-title><source>J Allergy Clin Immunol</source><volume>149</volume><year>2022</year><fpage>1383</fpage><lpage>1891.e17</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2021.10.023</pub-id><pub-id pub-id-type="pmid">34740607</pub-id>
</element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Fernandez-Rivas</surname><given-names>M.</given-names></name><name><surname>Vereda</surname><given-names>A.</given-names></name><name><surname>Vickery</surname><given-names>B.P.</given-names></name><name><surname>Sharma</surname><given-names>V.</given-names></name><name><surname>Nilsson</surname><given-names>C.</given-names></name><name><surname>Muraro</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy</article-title><source>Allergy</source><volume>77</volume><year>2022</year><fpage>991</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1111/all.15027</pub-id><pub-id pub-id-type="pmid">34320250</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Nurmatov</surname><given-names>U.</given-names></name><name><surname>Devereux</surname><given-names>G.</given-names></name><name><surname>Worth</surname><given-names>A.</given-names></name><name><surname>Healy</surname><given-names>L.</given-names></name><name><surname>Sheikh</surname><given-names>A.</given-names></name></person-group><article-title>Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis</article-title><source>Br J Nutr</source><volume>111</volume><year>2014</year><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1017/s0007114513002353</pub-id><pub-id pub-id-type="pmid">23945022</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Narisety</surname><given-names>S.D.</given-names></name><name><surname>Frischmeyer-Guerrerio</surname><given-names>P.A.</given-names></name><name><surname>Keet</surname><given-names>C.A.</given-names></name><name><surname>Gorelik</surname><given-names>M.</given-names></name><name><surname>Schroeder</surname><given-names>J.</given-names></name><name><surname>Hamilton</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy</article-title><source>J Allergy Clin Immunol</source><volume>135</volume><year>2015</year><fpage>1275</fpage><lpage>1282.e1-6</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2014.11.005</pub-id><pub-id pub-id-type="pmid">25528358</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Vickery</surname><given-names>B.P.</given-names></name><name><surname>Vereda</surname><given-names>A.</given-names></name><name><surname>Casale</surname><given-names>T.B.</given-names></name><name><surname>Beyer</surname><given-names>K.</given-names></name><name><surname>du Toit</surname><given-names>G.</given-names></name><name><surname>O Hourihane</surname><given-names>J.</given-names></name><etal/></person-group><article-title>AR101 oral immunotherapy for peanut allergy</article-title><source>N Engl J Med</source><volume>379</volume><year>2018</year><fpage>1991</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1812856</pub-id><pub-id pub-id-type="pmid">30449234</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Feuille</surname><given-names>E.</given-names></name><name><surname>Nowak-W&#x00119;grzyn</surname><given-names>A.</given-names></name></person-group><article-title>Oral immunotherapy for food allergies</article-title><source>Ann Nutr Metab</source><volume>68</volume><issue>suppl&#x000a0;1</issue><year>2016</year><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1159/000445391</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>&#x000d6;zdemir</surname><given-names>P.G.</given-names></name><name><surname>Sato</surname><given-names>S.</given-names></name><name><surname>Yanagida</surname><given-names>N.</given-names></name><name><surname>Ebisawa</surname><given-names>M.</given-names></name></person-group><article-title>Oral immunotherapy in food allergy: where are we now?</article-title><source>Allergy Asthma Immunol Res</source><volume>15</volume><year>2023</year><fpage>125</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.4168/aair.2023.15.2.125</pub-id><pub-id pub-id-type="pmid">37021501</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="other" id="sref32"><person-group person-group-type="author"><collab>Palforzia. Peanut <italic>(Arachis hypogaea)</italic> allergen powder-dnfp</collab></person-group><article-title>Prescribing information. Aimmune Therapeutics</article-title><ext-link ext-link-type="uri" xlink:href="https://www.palforzia.com/sites/default/files/2023-03/stn125696-pi-clean.pdf" id="intref0095">https://www.palforzia.com/sites/default/files/2023-03/stn125696-pi-clean.pdf</ext-link><year>Updated July 2022</year></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Andorf</surname><given-names>S.</given-names></name><name><surname>Purington</surname><given-names>N.</given-names></name><name><surname>Block</surname><given-names>W.M.</given-names></name><name><surname>Long</surname><given-names>A.J.</given-names></name><name><surname>Tupa</surname><given-names>D.</given-names></name><name><surname>Brittain</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial</article-title><source>Lancet Gastroenterol Hepatol</source><volume>3</volume><year>2018</year><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/s2468-1253(17)30392-8</pub-id><pub-id pub-id-type="pmid">29242014</pub-id>
</element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>B&#x000e9;gin</surname><given-names>P.</given-names></name><name><surname>Dominguez</surname><given-names>T.</given-names></name><name><surname>Wilson</surname><given-names>S.P.</given-names></name><name><surname>Bacal</surname><given-names>L.</given-names></name><name><surname>Mehrota</surname><given-names>A.</given-names></name><name><surname>Kausch</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab</article-title><source>Allergy Asthma Clin Immunol</source><volume>10</volume><year>2014</year><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1710-1492-10-7</pub-id><pub-id pub-id-type="pmid">24576338</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>B&#x000e9;gin</surname><given-names>P.</given-names></name><name><surname>Winterroth</surname><given-names>L.C.</given-names></name><name><surname>Dominguez</surname><given-names>T.</given-names></name><name><surname>Wilson</surname><given-names>S.P.</given-names></name><name><surname>Bacal</surname><given-names>L.</given-names></name><name><surname>Mehrota</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Safety and feasibility of oral immunotherapy to multiple allergens for food allergy</article-title><source>Allergy Asthma Clin Immunol</source><volume>10</volume><year>2014</year><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1710-1492-10-1</pub-id><pub-id pub-id-type="pmid">24428859</pub-id>
</element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Sindher</surname><given-names>S.B.</given-names></name><name><surname>Kumar</surname><given-names>D.</given-names></name><name><surname>Cao</surname><given-names>S.</given-names></name><name><surname>Purington</surname><given-names>N.</given-names></name><name><surname>Long</surname><given-names>A.</given-names></name><name><surname>Sampath</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Phase 2, randomized multi oral immunotherapy with omalizumab &#x0201c;real life&#x0201d; study</article-title><source>Allergy</source><volume>77</volume><year>2022</year><fpage>1873</fpage><lpage>1884</lpage><pub-id pub-id-type="doi">10.1111/all.15217</pub-id><pub-id pub-id-type="pmid">35014049</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>K.</given-names></name><name><surname>O Lewis</surname><given-names>M.</given-names></name><name><surname>Hanna</surname><given-names>E.</given-names></name><name><surname>Alfara</surname><given-names>M.K.C.</given-names></name><name><surname>Corrigan</surname><given-names>K.</given-names></name><name><surname>Buonanno</surname></name><etal/></person-group><article-title>Safety of multifood oral immunotherapy in children aged 1 to 18 years at an academic pediatric clinic</article-title><source>J Allergy Clin Immunol Pract</source><volume>11</volume><year>2023</year><fpage>1907</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2023.03.002</pub-id><pub-id pub-id-type="pmid">36907355</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Andorf</surname><given-names>S.</given-names></name><name><surname>Purington</surname><given-names>N.</given-names></name><name><surname>Kumar</surname><given-names>D.</given-names></name><name><surname>Long</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Laughlin</surname><given-names>K.L.</given-names></name><name><surname>Sicherer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals</article-title><source>EClinicalMedicine</source><volume>21</volume><year>2019</year><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2018.12.006</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="other" id="sref39"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group><article-title>Food allergies</article-title><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/food/food-labeling-nutrition/food-allergies" id="intref0100">https://www.fda.gov/food/food-labeling-nutrition/food-allergies</ext-link><year>Updated January 10, 2023</year></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>K.F.</given-names></name><name><surname>Altman</surname><given-names>D.G.</given-names></name><name><surname>Moher</surname><given-names>D.</given-names></name></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title><source>BMJ</source><volume>340</volume><year>2010</year><object-id pub-id-type="publisher-id">c332</object-id><pub-id pub-id-type="doi">10.1136/bmj.c332</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>H.A.</given-names></name><name><surname>Gerth van Wijk</surname><given-names>R.</given-names></name><name><surname>Bindslev-Jensen</surname><given-names>C.</given-names></name><name><surname>Sicherer</surname><given-names>S.</given-names></name><name><surname>Teuber</surname><given-names>S.S.</given-names></name><name><surname>Burks</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma &#x00026; Immunology&#x02013;European Academy of Allergy and Clinical Immunology PRACTALL consensus report</article-title><source>J Allergy Clin Immunol</source><volume>130</volume><year>2012</year><fpage>1260</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2012.10.017</pub-id><pub-id pub-id-type="pmid">23195525</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Burks</surname><given-names>A.W.</given-names></name><name><surname>Jones</surname><given-names>S.M.</given-names></name><name><surname>Wood</surname><given-names>R.A.</given-names></name><name><surname>Fleischer</surname><given-names>D.M.</given-names></name><name><surname>Sicherer</surname><given-names>S.H.</given-names></name><name><surname>Lindblad</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>Oral immunotherapy for treatment of egg allergy in children</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200435</pub-id><pub-id pub-id-type="pmid">22808958</pub-id>
</element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Simes</surname><given-names>R.J.</given-names></name></person-group><article-title>An improved Bonferroni procedure for multiple tests of significance</article-title><source>Biometrika</source><volume>73</volume><year>1986</year><fpage>751</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1093/biomet/73.3.751</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>S.</given-names></name></person-group><article-title>A simple sequentially rejective multiple test procedure</article-title><source>Scand J Stat</source><volume>6</volume><year>1979</year><fpage>65</fpage><lpage>70</lpage></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Baumert</surname><given-names>J.L.</given-names></name><name><surname>Taylor</surname><given-names>S.L.</given-names></name><name><surname>Koppelman</surname><given-names>S.J.</given-names></name></person-group><article-title>Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy</article-title><source>J Allergy Clin Immunol Pract</source><volume>6</volume><year>2018</year><fpage>457</fpage><lpage>465.e4</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2017.05.006</pub-id><pub-id pub-id-type="pmid">28669889</pub-id>
</element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>O&#x02019;B Hourihane</surname><given-names>J.</given-names></name><name><surname>Beyer</surname><given-names>K.</given-names></name><name><surname>Abbas</surname><given-names>A.</given-names></name><name><surname>Fernandez-Rivas</surname><given-names>M.</given-names></name><name><surname>Turner</surname><given-names>P.J.</given-names></name><name><surname>Blumchen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial</article-title><source>Lancet Child Adolesc Health</source><volume>4</volume><year>2020</year><fpage>728</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1016/s2352-4642(20)30234-0</pub-id><pub-id pub-id-type="pmid">32702315</pub-id>
</element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>J.A.</given-names></name><name><surname>Leonard</surname><given-names>S.</given-names></name><name><surname>Groetch</surname><given-names>M.</given-names></name><name><surname>Assa&#x02019;ad</surname><given-names>A.</given-names></name><name><surname>Cianferoni</surname><given-names>A.</given-names></name><name><surname>Clark</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Conducting an oral food challenge: an update to the 2009 Adverse Reactions to Foods Committee work group report</article-title><source>J Allergy Clin Immunol Pract</source><volume>8</volume><year>2020</year><fpage>75</fpage><lpage>90.e17</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2019.09.029</pub-id><pub-id pub-id-type="pmid">31950914</pub-id>
</element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary data</title><p id="p0255">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary Figs and Tables</title></caption><media xlink:href="mmc1.docx"/></supplementary-material>
</p></sec><ack id="ack0010"><p id="p0250">We thank all Harmony trial participants and their families; all investigators, study coordinators, and staff at participating study sites; and institutional review boards in addition to the independent data monitoring committee. A&#x000a0;list of the Harmony investigators can be found in the Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0085">www.jaci-global.org</ext-link>. Medical writing support was funded by Alladapt Immunotherapeutics Inc and provided by Dionne Turnbull, PhD, and Kathryn H. Condon, PhD, CMPP, of Koahana Inc.</p></ack></back></article>